AVXL
Anavex Life Sciences Corp. Healthcare Biotechnology
7/12
Innovation Score
Red Flags (1)
HYPE_PRICING ($0.0M rev, $270M mcap)
Patent Activity
3/3
11 patents found
FUZZY
Cash Runway
2/3
46 months of cash remaining based on current burn rate.
Cash on hand: $131.7M
Cash on hand: $131.7M
Revenue Trajectory
1/3
Revenue: $0.0M
Revenue growth data unavailable.
Revenue growth data unavailable.
Management Quality
1/3
Insider ownership: 3.1%
SBC/Revenue: 0.0%
No reverse splits detected
SBC/Revenue: 0.0%
No reverse splits detected
Key Metrics
Market Cap
$269.7M
Revenue
$0.0M
Revenue Growth (YoY)
N/A
Cash on Hand
$131.7M
Cash Runway
46 months
Shares Outstanding
92.7M
Insider Ownership
3.1%
SBC / Revenue
0.0%
Sector / Industry
Healthcare / Biotechnology
Patents (11)
Match type: FUZZY — company name matched partially; verify assignee
- A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
- Neurodevelopmental disorder therapy
- Enantiomers of A2-73, analogues, and sigma agonist activity
- Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
- Treatment of cardiac dysfunction
7-Step Risk Assessment
How AVXL maps to our micro cap methodology:
- Innovation Signal 11 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 46 months of runway. Comfortable buffer for execution.
- Revenue Trajectory Revenue data unavailable.
- Management Alignment Insiders hold 3.1% of shares. SBC is 0.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $269.7M company.
Financial Detail
Free Cash Flow
$-21.8M
FCF Yield
-8.1%
Return on Equity
-33.6%
Debt / Equity
N/A
Gross Margin
N/A
Profit Margin
N/A
Operating Margin
N/A
Price / Book
2.13
Current Ratio
20.87
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-05-16